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Abstract: Patient-based measures of subjective health status
are increasingly used as outcome measures in interventional
trials. We aimed to determine the variability and predictors
of subjective health ratings in a possible target group for
future interventions: the spinocerebellar ataxias (SCAs). A
consecutive sample of 526 patients with otherwise unex-
plained progressive ataxia and genetic diagnoses of SCA1
(117), SCA2 (163), SCA3 (139), and SCA6 (107) were
enrolled at 18 European referral centers. Subjective health
status was assessed with a generic measure of health related
quality of life, the EQ-5D (Euroqol) questionnaire. In addi-
tion, we performed a neurological examination and a screen-
ing questionnaire for affective disorders (patient health ques-
tionnaire). Patient-reported health status was compromised in
patients of all genotypes (EQ-5D visual analogue scale (EQ-
VAS) mean 61.45 6 20.8). Speciﬁcally, problems were
reported in the dimensions of mobility (86.9% of patients),
usual activities (68%), pain/discomfort (49.4%), depression/
anxiety (46.4%), and self care (38.2%). Multivariate analysis
revealed three independent predictors of subjective health sta-
tus: ataxia severity, extent of noncerebellar involvement, and
the presence of depressive syndrome. This model explained
30.5% of EQ-VAS variance in the whole sample and might
be extrapolated to other SCA genotypes.  2010 Movement
Disorder Society
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The spinocerebellar ataxias (SCAs) are a clinical
and genetically heterogeneous group of autosomal
dominantly inherited progressive cerebellar disorders.
Up to now, >25 different gene loci have been found.
In >15 SCAs, the affected genes and causative muta-
tions have been identiﬁed. The most common SCAs,
which together account for more than half of all
affected families, are SCA1, SCA2, SCA3, and SCA6.
Each of these disorders is caused by a translated CAG
repeat expansion mutation.
Recently, there has been major progress in the
development of rater-based clinical assessment instru-
ments for SCAs1 and the identiﬁcation of factors that
determine disease severity measured by these instru-
ments.2 However, studies in various neurodegenerative
disorders have shown that subjective health status is
only partly related to disease-related factors that are
assessed by clinical instruments. Other factors, such as
emotional well-being, coping strategies, and comorbid-
ity may play a role for health perception.3 Therefore,
patient-based measures are increasingly considered to
be important for the outcome assessment in interven-
tional trials. There are two types of instruments to
assess subjective health status. Disease-speciﬁc instru-
ments like the Parkinson’s disease questionnaire-39 for
Parkinson’s disease4 have been developed to assess the
impact of one speciﬁc disease on health perception.
They have the advantage of a high-discriminant ability
in that disease. In contrast, generic instruments like the
medical outcome study, 36-item short form5 or mea-
sure of health related quality of life, part one: ﬁve
dimensions (EQ-5D)6 can be used in patients suffering
from various diseases. They are less speciﬁc, but allow
comparisons between diseases or of patient groups
with the general population.
To study subjective health perception in patients
with SCA1, SCA2, SCA3, and SCA6 we used the
generic instrument EQ-5D, which is easy to administer,
can be obtained from the public domain, and is avail-
able in validated translations in various languages.
EQ-5D has been formally tested for practicality, reli-
ability, and validity (see www.euroqol.org), and popu-
lation norms are available for different populations.7–10
To evaluate a possible impact of emotional disturb-
ance on subjective health status, we assessed symptoms
of depression or anxiety with parts of the patient health
questionnaire (PHQ). The PHQ was developed and
validated to screen for psychiatric comorbidity in gen-
eral medical practice in accordance with criteria of the
American Psychiatric Association11,12 and has been
translated into various languages. The data reported
here were collected during the ongoing EUROSCA
natural history study (www.eurosca.org).
PATIENTS AND METHODS
Patients
The study was performed at 17 European centers
which together form the EUROSCA clinical group.
Inclusion criteria were progressive, otherwise unex-
plained ataxia and a positive molecular genetic testing
for either SCA1, SCA2, SCA3, or SCA6. Cases were
ascertained with the help of an electronic patient regis-
try that contains data of all SCA patients that have
been in contact with one of the study centers. Patients
were consecutively recruited within a predetermined
period between July 2005 and August 2006. The study
population consisted of 526 patients (SCA1:
117 patients from 90 families, SCA2: 163 patients
from 103 families, SCA3: 139 patients from 107 fami-
lies, SCA6: 107 patients from 81 families). The study
was approved by the ethics committees of the contrib-
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uting centers. Written informed consent was obtained
from each participant.
Measure of Health Related Quality of Life, Part
One: Five Dimensions
Paper copies of the EQ-5D p.1–3 and selected PHQ
items (question 1a–1i: depressive symptoms; question
2a–2e: anxiety symptoms, question 3: impairment by
reported symptoms) were distributed and ﬁlled in on-
site. If single questions were found unanswered on
return, probands were prompted to try and answer this
question. If they felt unable to answer a question, that
item was reported as missing.
The EQ-5D dimensions mobility, self-care, usual
activities, pain/bodily discomfort (named ‘‘EQ-5D
pain’’ in Results section), anxiety/depression (named
‘‘EQ-5D mood’’ in Results section) are answered as
1 (no problem), 2 (some problem), or 3 (severe prob-
lem). The visual analogue scale (EQ-VAS) yields a
number of 0 to 100 between the anchors ‘‘worst imagi-
nable health state’’ (0) and ‘‘best imaginable health
state’’ (100).
Patient Health Questionnaire
Answers in PHQ items were used for algorithmic
classiﬁcations as ‘‘no depressive syndrome—any
depressive syndrome’’ and ‘‘no anxiety syndrome—any
anxiety syndrome’’ as described previously11 and given
as relative frequencies. For the anxiety classiﬁcations,
because some patients deviated from the conditioned
answers in question 2b to 2e (answer only if 2a has
been answered yes), we performed a sensitivity
analysis with exclusion and after inclusion of such
cases which did not change the results in terms of
signiﬁcance.
Clinical Assessment
Severity of ataxia was assessed clinically with the
scale for the assessment and rating of ataxia (SARA)1
scoring from 0 (no ataxia) to 40 (most severe ataxia).
Additional extracerebellar signs or symptoms were
assessed as present or absent with the inventory of
nonataxia symptoms (INAS). A sum score from 0 to
16 was formed from the number of signs or symptoms
present in each patient (INAS count). The details of
SARA scores and INAS count in this patient sample
have been reported elsewhere.2
Statistical Analysis
The results of EQ-5D dimensions are reported as
frequency distributions. Differences between genotypes
were tested with Chi-square test or Fisher’s exact test
when appropriate.
Individual domains of EQ-5D were treated as
nominal variables and the relation between EQ-5D
dimensions and the ordinal variables age, age at onset,
disease duration, SARA, and INAS count tested using
univariate ANOVA. P-values were Bonferroni
corrected since there are ﬁve EQ-5D dimensions.
Results of the EQ-VAS were treated as quantitative
variables. Correlations between EQ-VAS and ordinal
variables were studied with Pearson’s correlation coef-
ﬁcients and the relation between EQ-VAS and nominal
variables was analyzed using univariate ANOVA.
The relation of EQ-VAS with PHQ classiﬁcations
and single INAS count components was tested using
simple logistic regressions. The generalized estimating
equations approach was used to adjust on family
effect.
For the whole sample, a mixed linear model of
EQ-VAS as dependent variable was performed with
gender, age, disease duration, SARA, INAS count, and
PHQ depression/anxiety categories included as
independent variables. The model was obtained with
stepwise selection. Genotype, family, and country were
regarded as random effects for adjustment.
All tests were two-sided and considered signiﬁcant
when P < 0.05. Statistics were computed using SAS
8.2 (SAS Institute, Cary, NC).
RESULTS
Patient characteristics are given in Table 1. SCA6
patients were of older age and showed less extracere-
bellar signs (lower INAS count), whereas sex ratio,
disease duration, and disease severity as measured by
SARA did not differ between genotypes. The EQ-5D
was not applied in ﬁve cases due to reading or lan-
guage difﬁculties. Of the 521 patients who completed,
data were missing in <2% of all items (EQ-VAS:
9 patients, EQ-5D pain/discomfort and anxiety/depres-
sion items: 2). Assignment to the PHQ categories of
depressive or anxiety syndrome was possible in 515
and 503 cases.
The EQ-5D and PHQ results are given in Table 2.
Among the ﬁve EQ-5D dimensions, patients reported
most frequently problems with mobility and usual
activities (86.9% and 68%). Approximately half of the
patients considered pain or depression/anxiety as a
problem and only 38% of the patients reported prob-
lems with self care. The median EQ-VAS was 61.5.
According to the PHQ ratings, 17% of the patients
were categorized as ‘‘any depressive syndrome’’ and
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14% as ‘‘any anxiety syndrome.’’ There were no differ-
ences between the genotypes except in the EQ-5D
dimension of pain/bodily discomfort, where problems
were reported more frequently by SCA3 patients than
by patients with one of the other genotypes (P 5
0.015). Therefore, subsequent analyses of EQ-VAS
were only performed for the whole group.
To screen for factors that might determine subjective
health status, we tested for relations between EQ-VAS
and demographic and disease-related factors. EQ-VAS
decreased with disease duration (Pearson r 5 20.21,
P < 0.001), while it was not correlated with age or
age at disease onset. EQ-VAS did not differ between
men and women. Patients with higher SARA ratings
scored themselves lower on EQ-VAS (r 5 20.37, P <
0.001). In addition, higher SARA ratings were
observed in patients who reported problems in any of
the EQ-5D dimensions (P < 0.001 except pain P 5
0.003; Fig. 1). Similarly, there were higher INAS
count, that is more extracerebellar symptoms, among
the patients who had lower EQ-VAS ratings (Spearman
Tau 5 20.32, P < 0.001) or reported more problems
in the dimensions mobility, self care, usual activities
(all P < 0.001) and mood (P 5 0.002). Among the 16
nonataxia symptoms recorded by INAS, only paresis,
urinary dysfunction, cognitive impairment (all P <
0.0001), dystonia (P 5 0.0012), areﬂexia (P 5
0.0018), and muscle atrophy (P 5 0.0024) were
TABLE 1. Patient characteristics
SCA1
(n 5 117)
SCA2
(n 5 163)
SCA3
(n 5 139)
SCA6
(n 5 107)
Comparison
between
genotypes
Whole
sample
(n 5 526)
Gender (M/F) 71/46 75/88 73/66 58/49 NS 277/249
Age (yr) 46.33 6 12.25 46.34 6 13.27 48.76 6 11.80 64.88 6 11.05 <0.001 50.72 6 14.17
Age at onset (yr) 36.96 6 10.64 34.89 6 12.74 37.07 6 11.38 54.46 6 10.25 <0.001 39.91 6 13.62
Disease duration (yr) 9.53 6 5.47 11.34 6 6.52 11.62 6 5.93 10.42 6 6.44 NS 10.82 6 6.16
Nb of repeat longer allele 47.39 6 5.23 39.33 6 3.24 68.84 6 4.63 22.36 6 0.94 – –
Nb of repeat shorter allele 29.89 6 1.69 22.19 6 1.41 21.72 6 5.03 12.59 6 1.15 – –
SARA sum score 15.58 6 9.08 15.78 6 8.00 15.15 6 8.57 15.00 6 6.56 NS 15.41 6- 8.13
INAS count 4.98 6 2.28 4.63 6 2.16 5.22 6 2.55 2.04 6 1.75 <0.001 4.34 6 2.51
Data are expressed as numbers or mean 6 standard deviation.
TABLE 2. Patient ratings on EQ-5D and PHQ assignment to depression or anxiety syndrome
Item
Answer
options SCA1 SCA2 SCA3 SCA6
Comparison
between
genotypes*
Whole
sample
EQ-5D
mobility
No problem 11/115 (9.6) 25/162 (15.4) 19/137 (13.9) 13/107 (12.2) NS 68/521 (13.1)
Some problem 99/115 (86.1) 129/162 (79.6) 110/137 (80.3) 93/107 (86.9) 431/521 (82.7)
Severe problem 5/115 (4.4) 8/162 (4.9) 8/137 (5.8) 1/107 (0.9) 22/521 (4.2)
EQ-5D
self care
No problem 65/115 (56.5) 104/162 (64.2) 88/137 (64.2) 65/107 (60.8) NS 322/521 (61.8)
Some problem 40/115 (34.8) 47/162 (29) 39/137 (28.5) 38/107 (35.5) 164/521 (31.5)
Severe problem 10/115 (8.7) 11/162 (6.8) 10/137 (7.3) 4/107 (3.7) 35/521 (6.7)
EQ-5D
usual activities
No problem 32/115 (27.8) 68/162 (42) 44/137 (32.1) 23/107 (21.5) NS 167/521 (32.1)
Some problem 63/115 (54.8) 75/162 (46.3) 73/137 (53.3) 68/107 (63.6) 279/521 (53.6)
Severe problem 20/115 (17.4) 19/162 (11.7) 20/137 (14.6) 16/107 (15) 75/521 (14.4)
EQ-5D
pain/discomfort
No problem 53/114 (46.5) 90/162 (55.6) 54/136 (39.7) 66/107 (61.7) 0.015* 263/519 (50.7)
Some problem 57/114 (50) 66/162 (40.7) 73/136 (53.7) 41/107 (38.3) 237/519 (45.7)
Severe problem 4/114 (3.5) 6/162 (3.7) 9/136 (6.6) 0/107 (0) 19/519 (3.7)
EQ-5D anxiety/
depression
No problem 56/114 (49.1) 90/162 (55.6) 70/136 (51.5) 62/107 (58) NS 278/519 (53.6)
Some problem 52/114 (45.6) 60/162 (37) 54/136 (39.7) 39/107 (36.5) 205/519 (39.5)
Severe problem 6/114 (5.3) 12/162 (7.4) 12/136 (8.8) 6/107 (5.6) 36/519 (6.9)
EQ-VAS 59.6 6 21.9 63.3 6 20.5 59.1 6 21.6 63.7 6 19 NS 61.45 6 20.8
60 65 60 70 61.5
(0–100) (0–100) (0–99) (20–100) (0–100)
PHQa
depression
25/114 (21.9) 25/157 (15.9) 25/137 (18.3) 12/107 (11.2) NS 87/515 (16.9)
PHQa anxiety 20/110 (18.2) 22/156 (14.1) 14/131 (10.7) 15/106 (14.2) NS 71/503 (14.1)
Data are expressed as frequency/sample size (%) or mean 6 standard deviation, median (range).
*For EQ-5D dimensions: P-value adjusted for multiple comparisons.
aClassiﬁcation as any depressive syndrome or any anxiety syndrome respectively as described in Patients and Methods section.
590 T. SCHMITZ-HU¨BSCH ET AL.
Movement Disorders, Vol. 25, No. 5, 2010
associated with lower EQ-VAS ratings, but not
hyperreﬂexia, extensor plantar response, spasticity,
fasciculations, myoclonus, rigidity, chorea/dyskinesia,
resting tremor, sensory symptoms, or brainstem oculo-
motor signs (Bonferroni corrected signiﬁcance level set
at 0.0031).
Patients classiﬁed as having any depressive syn-
drome or any anxiety syndrome according to PHQ
were all more likely to give worse EQ-VAS ratings
(depressive: 47.7 6 21.2 vs. 64.5 6 19.4, P < 0.001;
anxiety: 56.3 6 21.0 vs. 62.6 6 20.6, P 5 0.015).
Patients classiﬁed as having any depressive syndrome
were more likely to report more severe problems in all
EQ-5D dimensions. In contrast, patients classiﬁed as
having any anxiety syndrome were more likely to
report problems in usual activities, pain and mood, but
not in mobility and self care.
To understand which factors independently
determine subjective health status, we performed a
multivariate analysis using a mixed linear model with
EQ-VAS as dependent variable and gender, age, dis-
ease duration, SARA, INAS count, and PHQ categories
of depression and anxiety syndrome as independent
variables (family, center, and genotype included as ran-
dom effects). Ataxia severity, the number of extracere-
bellar symptoms and the presence of PHQ-depression
all independently affected EQ-VAS (Table 3). This
yielded a model that explained 30.5% of EQ-VAS
variability in our sample.
DISCUSSION
We evaluated the self-reported health status in a
large multinational group of patients with SCA1,
SCA2, SCA3, and SCA6 and aimed to explore predic-
tive factors. There were no differences between geno-
types in EQ-VAS ratings and EQ-5D dimensions
(except pain dimension) in unweighted comparison.
This ﬁnding is interesting, as SCA6 patients differed
clinically from the other genotypes in our group with
respect to age and extent of extracerebellar involve-
ment. The more frequent reporting of problems with
pain/bodily discomfort in SCA3 could be associated
with the more frequent occurrence of dystonia in this
genotype (24% in SCA3 vs. 5–14% in other genotypes,
Ref. 2). However, such link could not be proven in our
sample (P 5 0.098, Fisher exact test). Numerous
studies reported decreased subjective health status in
probands with neurological or other chronic diseases in
comparison with population means. In our study, such
comparison is hampered by the fact that subjective
health ratings are thought to differ between countries
due to differences in health care and general value set-
tings.13 Population surveys are currently not available
for all countries who contributed to our study. In com-
parison with the most recent German data set8 with an
EQ-VAS mean of 77.4 6 19 or the ﬁrst UK sample9
with 83.4 6 22, the SCA patients of all genotypes had
lower average scores. Taking this difference as a surro-
gate for ‘‘burden of disease’’—with all theoretical limi-
tations to that concept—the impact of disease on health
perception in our group is comparable with previous
reports in patients with Friedreich’s ataxia (EQ-VAS
64.9 6 19.1),14 epilepsy (61.6 6 20.3),15 or Parkin-
son’s disease (64.0 6 22.8).16 Accordingly, the propor-
tions of our SCA patients who reported problems in
the EQ-5D dimensions of mobility (86.9%), self care
(38.2%), and usual activities (68%) exceed the respec-
tive mean frequencies from the available population
FIG. 1. Relation of the ﬁve EQ-5D dimensions to ataxia severity
(SARA sum score). **P < 0.001, *P 5 0.003.
TABLE 3. Analysis of the predictors of self-rated health
status (EQ-VAS)
Multivariate analysis Univariate analysis
Beta
coefﬁcient
P
(multivariate
analysis)
Pearson
coeff, OR
(univariate
analysis)
P
(univariate
analysis)
Intercept 77.09 – –
SARA score 20.67 <0001 20.37a <0.001
INAS count 20.98 0.0456 20.32a,b <0.001
PHQ—
depression
211.79 <0001 0.959c <0.0001
PHQ—
anxiety
– NS 0.986c 0.0145
Disease
duration
– NS 20.21a <0.001
Age – NS – NS
Gender – NS – NS
Genotype, family, and country as random effects. R2, 0.308;
22 logL, 3458.8.
aPearson coefﬁcient.
bAnalysis corrected by genotype.
cOR.
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surveys (<30% mobility, <10% self care, and <20%
usual activities7). For the dimensions of pain and
mood, the distinction from population norms is less
clear. Problems were reported by over 45% of our
patients in both dimensions, and the frequencies
reported from different population surveys show a
wide range from 19 to 64% (pain) and from 11 to 52%
(mood).7 This implies that these two dimensions are
possibly less determined by the SCA disease process.
Nevertheless, pain and emotional disturbance are
relevant for subjective health perception—as shown by
fair relation of all EQ-5D dimensions to EQ-VAS
ratings—and should be considered in patient care. Of
note, problems in these dimensions are usually not
captured by clinical assessments of disease severity.
In accordance with several studies in other dis-
eases,14,17–20 the determinants of health status in our
sample differ from those reported for the general popu-
lation. For example, the decrease of health status with
age reported in the general population or worse health
perception in women7 was not conﬁrmed in our sam-
ple. This is not surprising as factors that inﬂuence
health perception in nondiseased populations (like age
or gender) are likely overwhelmed by the impact of a
chronic disease.
The effect of SCA disease on subjective health sta-
tus could be speciﬁed as a negative correlation of EQ-
VAS with disease duration, ataxia severity (SARA),
and extent of extracerebellar affection (INAS count) in
univariate analyses. The correlation with the clinical
assessment of ataxia severity in our sample is similar
to the correlation of EQ-VAS and the disease-speciﬁc
scale Uniﬁed Multiple System Atrophy Rating Scale
(UMSARS) in multiple system atrophy.19 Interestingly,
such correlation was not found in Parkinson’s disease
using the widely accepted Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS) motor assessment of
disease severity.21 In our sample, a higher number of
noncerebellar symptoms was associated with lower
EQ-VAS ratings in all genotypes. Relevant symptoms
for self-rated health status like urinary dysfunction or
dystonia are not assessed by our clinical scale of
disease severity but are informative for patient counsel-
ing, as such symptoms might be amenable to sympto-
matic treatment. An effect of emotional disturbance
could be conﬁrmed by a relation with PHQ ratings:
both the presence of depressive and anxiety syndrome
were associated with lower EQ-VAS ratings. A role of
depressive symptoms for subjective health perception
has also been described in other neurological dis-
eases.22–24 In the multivariate model, when genotype,
family, and country were included as random effects,
only the extent of neurological symptoms (SARA and
INAS) and depressive status independently determined
subjective health ratings to a different extent. The
intercept of 77.09 roughly equals the EQ-VAS means
reported from general population surveys.7 Starting
from there, each SARA point increase will lead to an
average 0.67 reduction in EQ-VAS and each INAS
count increase to an EQ-VAS decrease of 0.98. How-
ever, depressive status will lead to a massive reduction
in EQ-VAS of 11.79, an effect that would otherwise
only be seen with an 18-point decrease in SARA
scores. This underlines the strong effect of depressive
symptoms on subjective health status in addition to
disease-speciﬁc impairments and the need for adequate
depression screening and treatment. In the light of
known differences in EQ-5D reporting between coun-
tries, the inclusion of country as a random factor in
our model might seem questionable. However, the
studied SCA genotypes exhibit signiﬁcant geographical
clustering among the centers who contributed, which
made it impossible to differentiate between effects of
country and genotype. The ﬁnal model had an explana-
tory power of 30.5%, which is comparable with other
studies using EQ-VAS that yielded models with R2 of
0.3822,24 or 0.2225 in stroke or R2 of 0.45 in MSA
patients.19 The unexplained quality of life (QoL) frac-
tion of variance is commonly attributed to other dis-
ease-related and disease-independent factors, which are
not covered by the items of the QoL questionnaire. For
example, it can be assumed that factors like fatigue26
or perceived social support20,27 that have been reported
to determine variability in QoL self-ratings in different
diseases, are also relevant in our sample but not
included among the EQ-5D dimensions. Future studies
thus might improve our model by inclusion of other
known determinants of subjective health ratings.
Recent criticism of the EQ-5D (and other frequently
used QoL tools)28,29 stated that such instruments do
not allow valid description of health related QoL as
they do not explore values, expectations, or coping.
We agree that the evaluation of such truly subjective
factors is warranted to improve predictive models, but
are aware that they are less amenable to a quantitative
approach. Nevertheless, our results show that the EQ-
5D does include important aspects like pain, social
interaction and mood that are not covered by clinical
assessment but are relevant for subjective health rat-
ings. The EQ-5D proved well applicable in our sample
and might help to evaluate the acceptance of therapeu-
tic interventions as well as the clinical relevance of
otherwise measured treatment effects. Its suitability as
an outcome measure for treatment studies in SCA
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patients that aim to ameliorate ataxia or slow down
disease progression remains to be determined.
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